Manier S, Dimopoulos M-A, Leleu XP, Moreau P, Cavo M, Goldschmidt H, Orlowski RZ, Tron M, Tekle C, Brégeault M-F, Shafer AT, Beksac M, Facon T. Isatuximab plus bortezomib, lenalidomide, and dexamethasone for transplant-ineligible newly diagnosed multiple myeloma patients: a frailty subgroup analysis of the IMROZ trial. haematol [Internet]. 2025Sep.1 [cited 2025Dec.19];110(9):2139-50. Available from: https://haematologica.org/article/view/11994